TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31477086

Group type: EXPERIMENTAL
Intervention: Online intervention as indicated prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive personalized modular outpatient treatment
Number of subjects: 0
Study: 30563642

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole and Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 27512051

Group type: EXPERIMENTAL
Intervention: TEXT ME text message intervention
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: TEXT ME text message intervention + cardiac rehabilitation
Number of subjects: 710

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 710
Study: 24592906

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 25
Study: 22353804

Group type: EXPERIMENTAL
Intervention: MSI-H colon cancer (n=34)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Beta2-Microglobulin mutations in MSI-H colon cancers (10 out of 34)
Number of subjects: 223

Group type: COMPARATOR
Intervention: MSS colon cancer (n=189)
Number of subjects: 223
Study: 20068432

Group type: EXPERIMENTAL
Intervention: Exercise interventions (aerobic, strength, combined); specific dosages and durations not available
Number of subjects: 80

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 80
Study: 17103286

Group type: EXPERIMENTAL
Intervention: Ultrasound guided‐percutaneous drainage and i.v. antibiotics (ampicillin, cefuroxime, and metronidazole)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 50
Study: 14687173

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water only (baseline data)
Number of subjects: 18
Study: 12002921

Group type: EXPERIMENTAL
Intervention: Balanced inhalational anaesthesia and prophylactic dolasetron (group I+D)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Propofol TIVA and dolasetron (group T+D)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: TIVA alone (group T)
Number of subjects: 144
Study: 9818008

Group type: EXPERIMENTAL
Intervention: Genotropin (GH) 0.3 units/kg/day for 6 days before and after surgery
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo for 6 days before and after surgery
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Placebo for 6 days before and GH (0.3 units/kg/day) for 6 days after surgery
Number of subjects: 33
Study: 7528716

Group type: EXPERIMENTAL
Intervention: Zuzhongping
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dextran-40
Number of subjects: 46
Study: 2683921

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (20 1-g capsules for 12 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (safflower oil) supplementation
Number of subjects: 38
Study: 4174401

Group type: EXPERIMENTAL
Intervention: British gammaglobulin
Number of subjects: 87
Study: 30326006

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 400 mg to 800 mg 3 times a day for 8 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pregabalin (PGB) 150 mg to 300 mg twice daily for 8 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of GBP vs PGB
Number of subjects: 18
Study: 28389489

Group type: EXPERIMENTAL
Intervention: Interval Walking Training (IWT) supported by the smartphone-based InterWalk application for 8-12 weeks
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Interval Walking Training (IWT) with motivational support
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Interval Walking Training (IWT) without motivational support
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 246
Study: 25107946

Group type: EXPERIMENTAL
Intervention: 4 mm tip fully irrigated ablation catheter (CF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: standard 3.5 mm tip ablation catheter with six distal irrigation channels (6C)
Number of subjects: 60
Study: 23224298

Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor (Celecoxib)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (Celecoxib and placebo)
Number of subjects: 23
Study: 22089305

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18005368

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 50
Study: 17127538

Group type: EXPERIMENTAL
Intervention: Behavioral Naltrexone Therapy (BNT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Compliance Enhancement (CE)
Number of subjects: 69
Study: 12794092

Group type: EXPERIMENTAL
Intervention: 8 weeks of predominantly lower limb, combined aerobic and resistance training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (matched healthy control subjects)
Number of subjects: 10
Study: 11783256

Group type: EXPERIMENTAL
Intervention: Integrated Traditional Chinese and Western medicine (TCM-WM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 0
Study: 8732376

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups with TIMI 0 or 1 grade coronary patency
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups with TIMI 2 or 3 grade coronary flow
Number of subjects: 41
Study: 2009146

Group type: EXPERIMENTAL
Intervention: Delapril (15 mg twice daily)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Enalapril (10 mg daily, with potential doubling of dose if necessary)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Delapril and Enalapril with addition of hydrochlorothiazide (25 mg daily if target not reached)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Delapril and Enalapril
Number of subjects: 142
Study: 7051958

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31912678

Group type: EXPERIMENTAL
Intervention: ddPC (weekly paclitaxel and 3-weekly carboplatin)
Number of subjects: 73
Study: 30564920

Group type: EXPERIMENTAL
Intervention: Taeniectomy pouch
Number of subjects: 180

Group type: COMPARATOR
Intervention: Transverse coloplasty pouch
Number of subjects: 180
Study: 28798999

Group type: EXPERIMENTAL
Intervention: Yeast β‐glucan and mannan oligosaccharide (GM)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alginic acid (AC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Yeast nucleotides and RNA (NR)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bacillus strains (BS)
Number of subjects: 6

Group type: COMPARATOR
Intervention: High fish meal diet (C‐HF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Basal low fish meal diet (C‐LF)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Immunostimulant-supplemented diets
Number of subjects: 6
Study: 26230609

Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) rated as 'higher than others'
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) rated as 'similar to others'
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) rated as 'lower than others'
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Self-rated health (SRH)
Number of subjects: 1476
Study: 25139479

Group type: EXPERIMENTAL
Intervention: Transvaginal cholecystectomy (TVC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (CLC)
Number of subjects: 97
Study: 21858678

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.004% travoprost
Number of subjects: 42

Group type: COMPARATOR
Intervention: travoprost
Number of subjects: 42
Study: 19651668

Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity measured by Caltrac (1st tertile +4.81% change; 2nd tertile +4.60% change; 3rd tertile +7.23% change; p-trend = 0.018)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity measured by Digiwalker (1st tertile +3.76% change; 2nd tertile +6.25% change; 3rd tertile +7.25% change; p-trend = 0.001)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity
Number of subjects: 111
Study: 17065166

Group type: EXPERIMENTAL
Intervention: Loading dose of morphine (0.15 mg kg(‐1))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15868556

Group type: EXPERIMENTAL
Intervention: Endoscopic fetal tracheal occlusion (TO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard perinatal care (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at hospital discharge
Number of subjects: 24
Study: 11796399

Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ultrasonographic examination
Number of subjects: 31
Study: 9020454

Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet at ankle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pneumatic tourniquet at calf level
Number of subjects: 50
Study: 7942653

Group type: EXPERIMENTAL
Intervention: Cervical headgear/lower utility arch combination (CHG/LUA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cervical headgear alone (CHG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 3064717

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (BCG and 5-FU)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-FU)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 322
Study: 31791675

Group type: EXPERIMENTAL
Intervention: Ketamine (single subanesthetic-dose intravenous infusion)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 31162102

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 27923165

Group type: EXPERIMENTAL
Intervention: Outpatient priming with Foley catheter
Number of subjects: 130

Group type: COMPARATOR
Intervention: Inpatient priming with Foley catheter
Number of subjects: 130
Study: 25539518

Group type: EXPERIMENTAL
Intervention: Web-based eDoctoring (n=48)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Small-group Doctoring (n=71)
Number of subjects: 119
Study: 23974453

Group type: EXPERIMENTAL
Intervention: Routine mediolateral episiotomy
Number of subjects: 171

Group type: COMPARATOR
Intervention: Selective mediolateral episiotomy
Number of subjects: 171
Study: 21435214

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 1968
Study: 19242664

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 8057

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 8057

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 8057

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 8057

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 8057

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 8057
Study: 17208413

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus celecoxib 400 mg/day (200 mg bid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15124781

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer restorations
Number of subjects: 666

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 666
Study: 11423506

Group type: EXPERIMENTAL
Intervention: Nateglinide (60, 120, or 180 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nateglinide (60 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nateglinide (180 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nateglinide (higher doses)
Number of subjects: 15
Study: 11229181

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg/day for 15 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no vitamin E supplementation)
Number of subjects: 30
Study: 8481587

Group type: EXPERIMENTAL
Intervention: Etidronate (bisphosphonate)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Bone density measurement (2 standard deviations decrease)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Lowest quintile of bone density
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Highest quintile of bone density
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Simultaneous use of bone density and prevalent fractures
Number of subjects: 380
Study: 3320325

Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2758752

Group type: EXPERIMENTAL
Intervention: Out-patient lumbar radiculography with 10 ml iohexol (240 mgI/ml)
Number of subjects: 200

Group type: COMPARATOR
Intervention: In-patient controls
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Out-patient lumbar radiculography
Number of subjects: 200
Study: 30036174

Group type: EXPERIMENTAL
Intervention: Educational mobile application (game format)
Number of subjects: 43
Study: 27726304

Group type: EXPERIMENTAL
Intervention: 1-day, multi-professional, simulation-based team training focusing on crew resource management (CRM)
Number of subjects: 28657

Group type: COMPARATOR
Intervention: No team training (control)
Number of subjects: 28657
Study: 25791185

Group type: EXPERIMENTAL
Intervention: Rumba dance and nutrition education (n = 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional care (n = 29)
Number of subjects: 59
Study: 24229826

Group type: EXPERIMENTAL
Intervention: Smartinhaler Tracker electronic monitor
Number of subjects: 303
Study: 21922978

Group type: EXPERIMENTAL
Intervention: Fascia grafts
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cartilage grafts
Number of subjects: 38
Study: 19966701

Group type: EXPERIMENTAL
Intervention: Minimally invasive, endovascular methods of treatment
Number of subjects: 6000
Study: 16723553

Group type: EXPERIMENTAL
Intervention: Voriconazole at 400 mg twice daily on the first day and 200 mg twice daily on the second day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluconazole at 400 mg on the first day and 200 mg on the second day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (Ibuprofen alone)
Number of subjects: 12
Study: 15596634

Group type: EXPERIMENTAL
Intervention: Hostility in high-risk women
Number of subjects: 3733

Group type: EXPERIMENTAL
Intervention: Hostility in average-risk women
Number of subjects: 3733

Group type: EXPERIMENTAL
Intervention: Hostility in high-risk men
Number of subjects: 3733

Group type: EXPERIMENTAL
Intervention: Hostility in average-risk men
Number of subjects: 3733
Study: 11150432

Group type: EXPERIMENTAL
Intervention: Chemotherapy with etoposide, bleomycin, and high or standard dose cisplatin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Biopsy and chemotherapy without tumor resection
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resection at diagnosis followed by chemotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Biopsy followed by chemotherapy and post-chemotherapy tumor resection
Number of subjects: 36
Study: 9048702

Group type: EXPERIMENTAL
Intervention: SCID diagnosis and a battery of life event questionnaires (Intervention group, N = 33)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard diagnostic program (Referent group, N = 30)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SCID diagnosis and a battery of life event questionnaires (Intervention group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Experience of trauma (Intervention group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Psychometric indices (Intervention group)
Number of subjects: 63
Study: 8121966

Group type: EXPERIMENTAL
Intervention: AMPT (alpha‐methyl‐para‐tyrosine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diphenhydramine (active placebo)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SSRIs (fluoxetine, sertraline)
Number of subjects: 14
Study: 3314790

Group type: EXPERIMENTAL
Intervention: 0.9 mw continuous wave HeNe laser treatment
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (laser off)
Number of subjects: 81
Study: 30226133

Group type: EXPERIMENTAL
Intervention: Universal follow-up
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conditional follow-up
Number of subjects: 37
Study: 27138868

Group type: EXPERIMENTAL
Intervention: Proposed pegfilgrastim biosimilar
Number of subjects: 66

Group type: COMPARATOR
Intervention: US-licensed pegfilgrastim reference product
Number of subjects: 66
Study: 24506815

Group type: EXPERIMENTAL
Intervention: RRP (Retropubic Radical Prostatectomy)
Number of subjects: 339

Group type: COMPARATOR
Intervention: LRP (Laparoscopic Radical Prostatectomy)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: RRP
Number of subjects: 339

Group type: COMPARATOR
Intervention: LRP
Number of subjects: 339
Study: 22564086

Group type: EXPERIMENTAL
Intervention: Explicit rules to guide anticipation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verbal cueing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Implicit learning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Color cueing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study: 20394252

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% levobupivacaine with fentanyl 15 microg
Number of subjects: 40
Study: 17626986

Group type: EXPERIMENTAL
Intervention: Nadroparin (therapeutic doses throughout treatment)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Parnaparin (therapeutic doses for the first month, then prophylactic phase at half dose)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Both interventions (Nadroparin and Parnaparin)
Number of subjects: 91
Study: 15793400

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 2% lidocaine hydrochloride
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 16
Study: 12606735

Group type: EXPERIMENTAL
Intervention: 10 mg adefovir dipivoxil
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: 30 mg adefovir dipivoxil
Number of subjects: 515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study: 10077797

Group type: EXPERIMENTAL
Intervention: Fatiguing exercises of deltoid and rotator cuff
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rested state (before fatigue)
Number of subjects: 12
Study: 8808185

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PEP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study: 1878184

Group type: EXPERIMENTAL
Intervention: Interaction coaching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 6114677

Group type: EXPERIMENTAL
Intervention: Nadolol 2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Labetalol 1%
Number of subjects: 0
Study: 31310470

Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg lorazepam per os (PO) twice before the operation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no anxiolytic premedication)
Number of subjects: 61
Study: 29352723

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4684

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4684
Study: 25476995

Group type: EXPERIMENTAL
Intervention: 100 mg oral ibandronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.0 mg i.v. ibandronate
Number of subjects: 0
Study: 25189523

Group type: EXPERIMENTAL
Intervention: H‐HOPE intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 198
Study: 22251482

Group type: EXPERIMENTAL
Intervention: FBS0701 at 14.5 mg/kg/d
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: FBS0701 at 29 mg/kg/d
Number of subjects: 51
Study: 19177255

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 403

Group type: COMPARATOR
Intervention: Transdermal E2/NETA 50 microg/140 microg
Number of subjects: 403
Study: 17192289

Group type: EXPERIMENTAL
Intervention: Combined SST and GHRH/arginine test
Number of subjects: 24

Group type: COMPARATOR
Intervention: SST alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: GHRH/arginine test alone
Number of subjects: 24
Study: 14999462

Group type: EXPERIMENTAL
Intervention: Interactive training for GPs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11666126

Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA) at 120 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA) at 60 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9579130

Group type: EXPERIMENTAL
Intervention: Abdominal wall injection of low-dose heparin
Number of subjects: 114

Group type: COMPARATOR
Intervention: Upper limb injection of low-dose heparin
Number of subjects: 114
Study: 7706983

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 14